Attovia, Braveheart, Scribe, and Apnimed seek public listings amid a biotech rally and rising M&A activity.
Four biotech companies—Attovia Therapeutics, Braveheart, Scribe Therapeutics, and Apnimed—have filed for IPOs in July, capitalizing on a sector rebound. The move follows a surge in biotech stocks, which hit their highest levels since February 2021, driven by increased M&A activity and improved market sentiment.
Attovia focuses on immune-mediated diseases, while Braveheart develops cardiovascular drugs. Scribe aims to expand gene therapies for common conditions, and Apnimed targets obstructive sleep apnea treatments. Proceeds from the IPOs will fund clinical trials, drug approvals, and commercialization efforts.
The flurry of filings reflects renewed investor appetite for biotech, though market conditions remain volatile. No immediate pricing details were disclosed.